Your browser doesn't support javascript.
loading
Subventricular zone contacting glioblastoma: tumor size, molecular biological factors and patient survival.
Hallaert, G; Pinson, H; Van den Broecke, C; Vanhauwaert, D; Van Roost, D; Boterberg, T; Kalala, J P.
Afiliação
  • Hallaert G; Department of Neurosurgery, Ghent University Hospital, Gent, Belgium.
  • Pinson H; Department of Neurosurgery, Ghent University Hospital, Gent, Belgium.
  • Van den Broecke C; Department of Pathology, AZ St. Lucas Gent and Ghent University Hospital, Gent, Belgium.
  • Vanhauwaert D; Department of Neurosurgery, AZ Delta, Roeselare, Belgium.
  • Van Roost D; Department of Neurosurgery, Ghent University Hospital, Gent, Belgium.
  • Boterberg T; Department of Radiation Oncology, Ghent University Hospital, Gent, Belgium.
  • Kalala JP; Department of Neurosurgery, Ghent University Hospital, Gent, Belgium.
Acta Oncol ; 59(12): 1474-1479, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32672481
ABSTRACT

BACKGROUND:

Several studies show that subventricular zone (SVZ) contact of glioblastoma at diagnosis is a negative prognosticator of survival. In this report, we study glioblastoma patient survival, molecular biological and MRI-based volumetric findings according to SVZ contact. PATIENTS AND

METHODS:

We conducted a retrospective study of adult patients diagnosed with supratentorial glioblastoma and uniformly treated with temozolomide-based chemoradiotherapy after surgery. The patient cohort was dichotomized according to tumor contact with the SVZ at diagnosis as determined on preoperative MR imaging. Tumor volume was measured using semi-automated segmentation technique. MGMT-gene promoter methylation and IDH mutation status were determined on stored tumor tissue. Kaplan-Meier survival curves were constructed. Cox regression analysis was used to adjust for known confounding factors of glioblastoma patient survival.

RESULTS:

A total of 214 patients were included in the study of whom 68% belonged to the SVZpos group. Median tumor volume was significantly larger in the SVZpos group (33,8 mL vs 15,6 mL; p < .001). MGMT-unmethylated glioblastoma was more frequent in the SVZpos group (61.4% vs 44.9%; p = .028). The overall survival and progression-free survival were 12.2 months and 5.9 months for the SVZpos patient group but 16.9 months and 10.3 months for the SVZneg group (log-rank p = .016 and .007 respectively). In multivariate Cox survival analysis, SVZ contact proved a negative prognostic parameter, independent from age, KPS, extent of resection, MGMT-methylation and IDH mutation status.

CONCLUSIONS:

This study confirms SVZ contact at diagnosis as an independent negative prognostic factor for glioblastoma patient survival. SVZpos glioblastoma had larger tumor size and a larger proportion of unmethylated tumors than SVZneg glioblastoma. Further research is needed to establish whether the observed differences are solely explained by a different molecular profile of SVZpos glioblastoma or by interaction of glioblastoma with the unique SVZ microenvironment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Acta Oncol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Acta Oncol Ano de publicação: 2020 Tipo de documento: Article